Unveiling the Mystery of Sleeping Pain Neurons
A groundbreaking discovery by researchers from The University of Texas at Dallas and their international counterparts has shed light on the molecular secrets of human sleeping nociceptors. These sensory neurons, often silent to external stimuli, are now understood to be pivotal in neuropathic pain, affecting nearly one in five American adults.
Dr. Ted Price, an Ashbel Smith Professor of Neuroscience at UT Dallas, emphasizes the significance of this finding, suggesting a potential pathway for developing chronic pain relief medications. "We've known about the role of these cells in neuropathic pain, but now we can identify them with incredible precision at the gene-expression level. This opens up exciting possibilities for future research and treatment development."
Sleeping nociceptors, a unique class of sensory neurons, can spontaneously activate, causing persistent pain without an apparent trigger. This makes them a critical focus for understanding and managing neuropathic pain conditions.
The cell bodies of sleeping nociceptors reside in the dorsal root ganglia, nerve clusters near the spine, acting as messengers between the peripheral and central nervous systems. While their functional properties have been known for some time, their distinct molecular characteristics remained elusive until now.
"Active sleeping nociceptors have been observed in various neuropathic pain conditions, including diabetic neuropathy, postherpetic neuralgia, and fibromyalgia," explains Dr. Price. "These cells are the prime suspects for the shooting, spontaneous pain experienced by neuropathy patients."
Led by Dr. Angelika Lampert, a neurophysiology professor at RWTH Aachen University in Germany, the research team employed high-resolution electrical recordings and genetic activity analysis to identify sleeping nociceptors within the broader nerve population.
To uncover the molecular profile of these neurons, the German researchers initially used isolated dorsal root ganglia from pigs, as porcine skin nociceptors closely resemble those in humans. Cross-species analyses confirmed the presence of the same molecular markers in both pig and human sensory neurons, characterized by the oncostatin M receptor and the neuropeptide somatostatin.
"Our work provides a new framework for understanding the molecular origins of neuropathic pain, offering concrete prospects for targeted therapy development," says Dr. Lampert.
Co-corresponding author Dr. Shreejoy Tripathy, an associate professor of psychiatry at the University of Toronto, led the bioinformatic integration of the data, linking the neurons' functional properties to their gene expression profiles. "This collaboration has produced a Rosetta stone for pain research, matching the electrical fingerprint of sleeping nociceptors to a specific genetic signature," adds Dr. Tripathy.
The project also involved Marisol Mancilla Moreno, a cognition and neuroscience doctoral student in Dr. Price's lab, who led the spatial sequencing portion, showing which genes are particularly active in different cell types. "We're now hoping to initiate a drug discovery project to silence these cells. The molecular dataset we've generated is incredibly comprehensive, and the modeling will be extremely instructive,"
The research team received support from the PRECISION Network, funded by the NIH's Helping to End Addiction Long-term Initiative, addressing the opioid crisis in the U.S. "The PRECISION Network has provided invaluable human data that was crucial to this project. The collaborative spirit and open-mindedness of all involved have been instrumental in advancing scientific knowledge,"
Dr. Lampert emphasizes the importance of collaboration: "Answering these complex questions requires the best minds in each field. The success of this study relies on the close integration of specialized centers like UT Dallas. This work is a testament to the power of interdisciplinary and international cooperation."
The study also involved researchers from Harvard Medical School, King's College Hospital in London, and various universities and research centers in Germany. Funding was provided by grants from the NIH, the German Research Foundation, and several other foundations and research councils.
This research offers a promising step forward in the quest to understand and manage neuropathic pain, highlighting the potential for targeted therapies and drug development.
